Il-Jin Kim

Il-Jin Kim is the Chair of the Oncology Biomarker Review Forum (OBRF) at Predicine. Additionally, Il-Jin is the President of Predicine University and leads the CDx & Pharma Program Team at Predicine. Prior to this role, Il-Jin served as the Vice President and Head of Clinical Development at Predicine, overseeing IVD/Companion Diagnostic liquid biopsy clinical trials. Il-Jin also founded SingularCure Inc., InToVi, and served as the Founder and CEO of Guardant Health. Il-Jin's extensive experience includes roles at UCSF, where they identified therapeutic targets and diagnostic markers for human cancers. Il-Jin holds a DVM in Veterinary Medicine, a PhD in Cancer Genetics and Tumor Biology, and a certificate in Clinical Research Conduct and Management.